Table II.
Identified MART-126-35 APLs exhibit differential capacities to generate MART-126-35-specific CTL populations from the PBMC of different melanoma patient donors.
| %M26 Tetramer Positive | ||||
|---|---|---|---|---|
| Patient | A27L | E26G | E26S | L33M |
| MelPt-A | 3.14 (1) | 1.68 (0.53) | 3.36 (1.07) | 0.98 (0.31) |
| MelPt-B | 2.97 (1) | 1.31 (0.44) | 4.3 (1.45) | 7.7 (2.6) |
| MelPt-C | 40.6 (1) | 45.6 (1.12) | 15.6 (0.38) | 41.1 (1.02) |
| MelPt-D | 0.65 (1) | 1.73 (2.66) | 3.43 (5.27) | 2.07 (3.1) |
| MelPt-E | 1.77 (1) | 8.42 (4.75) | 6.88 (3.88) | 24.2 (13.67) |
| MelPt-F | 5.45 (1) | 3.35 (0.61) | 3.72 (0.68) | 3.07 (0.56) |
| MelPt-G | 33.4 (1) | 1.89 (.06) | 1.75 (.05) | 2.37 (.07) |
| MelPt-H | 1.24 (1) | 2.03 (1.63) | 1.31 (1.06) | 2.77 (2.2) |
APLs were used to stimulate PBMC cultures in vitro. Following a 1-week secondary stimulation cells were stained with FITC-labeled anti-CD8 antibodies and APC-labeled HLA-A2/ MART-126-35 tetramers and analyzed by flow cytometry. Percent tetramer positive indicated. Fold difference relative to A27L is indicated in parentheses. Differences of more than two-fold are indicated in bold.